SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
LONDON, Aug. 01, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Wedbush PacGrow Healthcare Conference
Date: August 15, 2017
Time: 3:05 PM EDT
Location: New York, NY
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||
| Aubrey Powell / James White | ||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||
| ICR, Inc. (US Media and Investor enquiries) | ||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
